Unresolved questions

There is amyloidogenic processing, and nonamyloidogenic. The former is regulated by BACE1, the latter is α-secretase, which cleaves the dangerous stub (Forming the α-CTF (C-terminal fragment), or the APP intracellular domain (AICD)). Notice the fully intramembrane α-secretase. Real? Can’t be. Look at the cleavage site. Truncated and modified amyloid-beta species Note how there’s a possible BACE1→ADAM10 route. More fun is how there are other secretases like η and γ. APP exists in several isoforms ranging from 695 to 770 amino acids in length, including the domain from which the Aβ peptide derives Not just amyloid: physiological functions of the amyloid precursor protein family (Müller 2017) (Highly detailed, especially noncanonical δ/η stuff....

It’s April 2022 in a niche nootropics community, and the next potential superdrug has been discovered. Does the power it may hold have the potential to change the entire world as we know it? https://warosu.org/sci/?task=search2&ghost=false&search_text=&search_subject=&search_username=&search_tripcode=%21%21cu2HYeafqTG&search_email=&search_filename=&search_datefrom=&search_dateto=&search_media_hash=&search_op=all&search_del=dontcare&search_int=dontcare&search_ord=new&search_capcode=all&search_res=post Heavy metal chelator, especially 3+ ions (Ferric Iron, Aluminum, lead, mercury, chromium, zinc, copper, etc.) limited affinity for ferrous iron. Deferoxamine has a very high affinity and specificity for the ferric iron and chelates it in a 1:1 molar ratio; that is, 100 mg of deferoxamine will bind to and eliminate 8....